Alnylam Surpasses $50B Market Cap as Amvuttra Heart Disease Launch Impresses Wall Street

Alnylam Pharmaceuticals’ market capitalization exceeded $50 billion following strong Wall Street response to the launch of Amvuttra (vutrisiran) for heart disease (ATTR-CM) 2345.

Shares rose more than 15%, driven by robust Q2 2025 product revenues and rapid commercial uptake of Amvuttra in ATTR-cardiomyopathy 3.

Q2 2025 total net product revenues reached $672 million, up 64% year over year, with approximately $544 million coming from TTR therapies including Amvuttra 1.

Approximately 1,400 ATTR-CM patients were receiving Amvuttra as of June 30, 2025 1.

Amvuttra received regulatory approval for ATTR-CM in the EU, Brazil, UK, and Japan in Q2 2025 1.

Alnylam raised 2025 guidance for TTR franchise net revenues ($2.18–2.28 billion) and total net product revenues ($2.65–2.80 billion) 1.

Multiple analysts raised price targets, with some exceeding $400 per share, and the consensus rating remains a strong “buy” 45.

Sources:

1. https://investors.alnylam.com/press-release?id=29136

2. https://www.fiercepharma.com/pharma/alnylam-exceeds-50b-market-cap-amvuttra-heart-disease-launch-wows-wall-street

3. https://www.biopharmadive.com/news/alnylam-amvuttra-q2-2025-sales-ttr-cardiomyopathy-guidance/756477/

4. https://www.marketbeat.com/instant-alerts/alnylam-pharmaceuticals-nasdaqalny-stock-price-expected-to-rise-needham-company-llc-analyst-says-2025-07-31/

5. https://www.gurufocus.com/news/3027028/alnylam-alny-price-target-boosted-to-415-amid-strong-quarterly-performance